BeiGenes Phase 2 Trial Of Brukinsa In Patients With Respiratory Symptoms Of Covid-19 Fails To Meet Co-primary Endpoints

BeiGene, a global biotechnology company, announced that the phase 2 trial evaluating Brukinsa (zanubrutinib) in patients hospitalized with respiratory symptoms of Covid-19, requiring supplemental oxygen without mechanical ventilation, did not meet the co-primary efficacy endpoints of respiratory failure-free survival or reduction in days on oxygen as compared to placebo. There were no new or additional safety signals for zanubrutinib identified in the trial.“I am proud of the work by our teams at BeiGene and our research partners to further the understanding of the potential for BTK-inhibition against Covid-19-related respiratory distress. While the outcome of this phase 2 trial is disappointing, I am heartened by the speed at which we mobilized to launch a clinical trial to explore if zanubrutinib might be able to help in the global fight against Covid-19,” said Jane Huang, M.D., chief medical officer, Hematology, at BeiGene. “Our mission has been to explore ways we can help patients around the world, supported by scientific rigor and well-designed and executed trials like this.”BeiGene initiated patient enrollment in a phase 2 trial in the US evaluating zanubrutinib for the treatment of patients with Covid-19-related pulmonary distress in May 2020.Brukinsa (zanubrutinib) is a small molecule inhibitor of Bruton’s tyrosine kinase (BTK), discovered by BeiGene scientists. It is currently being evaluated globally in a broad pivotal clinical program as a monotherapy and in combination with other therapies to treat various B-cell malignancies.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!